"Dr David N. Cade, Chief Medical Officer of Sirtex Medical said "The presentation of the combined FOXFIRE analysis by Professor Sharma at ASCO now confirms that while SIR-Spheres plus systemic chemotherapy did not meet the primary endpoint of an overall survival advantage over chemotherapy alone, a statistically significant benefit was observed in objective response rates and liver-specific progression. "
"Also, the initial data presented from the SIRFLOX and FOXFIRE Global analyses, did confirm a statistically significant reduction in the risk of death for those patients who received SIR-Spheres plus chemotherapy with a right-sided primary colon cancer. "
This has to be very positive news for Sirtex!!!!
Ann: Combined FOXFIRE Study Data Presented at ASCO Annual Meeting, page-2
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.8¢ |
Change
0.003(1.43%) |
Mkt cap ! $75.34M | |||
| Open | High | Low | Value | Volume |
| 17.8¢ | 17.8¢ | 17.5¢ | $9.047K | 50.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 7293686 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1399496 | 11 |
View Market Depth
| Last trade - 15.01pm 26/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |